je.st
news
Tag: application review
Police Review Board Volunteer Application
2019-03-06 23:37:55| PortlandOnline
PDF Document, 144kbCategory: News
Tags: review
board
application
police
Land Use Review Application Supplemental Form
2019-02-05 01:53:14| PortlandOnline
Word Document, 229kbCategory: Personal Wireless Service Facility Applications
Tags: form
review
land
application
Tree Permit Violation Review Application
2018-06-13 21:12:03| PortlandOnline
PDF Document, 119kbCategory: Correcting Tree Code Violations
Tags: review
application
tree
permit
Tree Permit Violation Review Application
2018-06-13 19:07:17| PortlandOnline
PDF Document, 119kbCategory: Tree Problems
Tags: review
application
tree
permit
FDA Accepts Supplemental Biologics License Application, Assigns Priority Review and Grants Breakthrough Therapy Designation to Mercks KEYTRUDA (pembrolizumab) for First-Line Treatment of Patients with Advanced Non-Small Cell Lung Cancer
2016-09-07 12:45:00| Merck.com - Product News
Dateline City: KENILWORTH, N.J. Merck Has Also Submitted a Marketing Authorization Application to the European Medicines Agency for KEYTRUDA in the Same Patient Population Submissions Based on Data from KEYNOTE-024 Trial Showing Superior Progression-Free and Overall Survival Compared to Chemotherapy in Patients Whose Tumors Express High Levels of PD-L1 KENILWORTH, N.J.--(BUSINESS WIRE)--Merck (NYSE:MRK), known as MSD outside the United States and Canada, today announced that the U.S. Food and Drug Administration (FDA) has accepted for Priority Review the supplemental Biologics License Application (sBLA) for KEYTRUDA (pembrolizumab), the companys anti-PD-1 therapy, for the first-line treatment of patients with advanced non-small cell lung cancer (NSCLC) whose tumors express PD-L1, with a PDUFA, or target action, date of Dec. 24, 2016. Language: English Contact: MerckMedia:Pamela Eisele, 267-305-3558orCourtney Ronaldo, 908-236-1108orInvestors:Teri Loxam, 908-740-1986orAmy Klug, 908-740-1898 Ticker Slug: Ticker: MRK Exchange: NYSE read more
Tags: advanced
review
application
license